KEW Group provides genomic profiling and evidence-based clinical intelligence to help oncologists design individualized cancer treatments. Its CancerPlex test analyzes over four hundred cancer genes, detects actionable alterations for targeted therapies, and requires smaller tumor samples than many next-generation sequencing tests. The company also offers KEW Therapeutic Pathways and aims to couple patient-specific genomic data with clinical knowledge to inform treatment decisions and potential clinical trial participation. KEW plans to commercialize CancerPlex and KEW Therapeutic Pathways, expand partnership activities with Cardinal Health, and deploy the KEW Oncology Network. The company focuses on serving community oncology practices, noting that roughly 80 percent of U.S. cancer patients are treated in the community setting. KEW is privately held and recently completed a $16.8 million Series B to support these efforts. KEW Group offers genomics-based diagnostic services to inform treatment decisions for community oncologists, notably its CancerPlex gene-testing panel. The company provides KEW MDx tumor genomic testing and KEW TPx Therapeutic Pathways that integrate genomic information into care decisions. KEW says it serves community oncology practices across the U.S. and internationally and is working with seven oncology practices in six states to refine pathways for seven cancer types. The company participates with practices involved in a Center for Medicare and Medicaid Innovation grant testing a Community Oncology Medical Home model. KEW launched CancerPlex as its first product offering to expand access to multiplex, next-generation sequencing for tumor profiling. Management states the recently closed financing provides critical capital to build and expand the reach of its offerings to community oncologists.

Total raised

$17M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2015